TARA Biosystems, a biotech company developing “heart-on-a-chip” tissue models for drug discovery, toxicology and translational medicine applications announced today that it closed on a $9 million Series A financing. This financing will fuel the development of TARA’s growing portfolio of healthy cardiac tissues, cardiac disease models as well as a range of acute and chronic testing service products. The Series A round was co-led by Trancos Ventures and Morgan Noble.